<DOC>
	<DOCNO>NCT02038127</DOCNO>
	<brief_summary>Comparison - Biolimus-eluting stent , Biomatrix , Biomatrix Flex stent , Biosensors , Singapore - Everolimus-eluting stent , Xience V , Xience Prime , Xience Xpedition stent , Abbott , USA - Zotarolimus-eluting stent , Endeavor Resolute , Endeavor Resolute Integrity stent Medtronic , USA patient coronary artery disease treat percutaneous coronary intervention</brief_summary>
	<brief_title>Gangwon PCI Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Age &gt; 19 year Subject able verbally confirm understand risk , benefit treatment alternative receive drugeluting stent ( ) he/she his/her legally authorize representative provide write informed consent prior study related procedure Subject must significant stenosis ( &gt; 50 % visual estimate ) native instent coronary artery Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , acute myocardial infarction , positive functional study reversible change ECG consistent ischemia ) . In subject coronary artery stenosis &gt; 75 % , evidence myocardial ischemia document Subject know hypersensitivity contraindication follow medication : heparin , aspirin , clopidogrel , prasugrel , ticagrelor , biolimus A9 , everolimus , zotarolimus , stainless steel , cobalt chromium , contrast medium ( Patients document sensitivity contrast medium , effectively premedicated steroid diphenhydramine may enrol . However , true anaphylaxis prior contrast medium enrol . ) Subject use systemic ( intravenous ) biolimus A9 , everolimus zotarolimus within 12 month . Female subject childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study Subject plan elective surgical procedure would necessitate interruption antiplatelet first 12 month post enrollment Subject noncardiac comorbid condition life expectancy &lt; 2 year may result protocol noncompliance ( per site investigator 's medical judgment ) Subject cardiogenic shock presentation Subject actively participate another drug device investigational study , complete primary end point followup period</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>